CytoDyn elects five directors, ratifies auditor, and approves say-on-pay at 2022 annual meeting

1. Election of Directors ​ ​ ​ ​ Company Nominee ​ For ​ Withheld ​ Broker Non-Votes Tanya Durkee Urbach ​ 249,070,313 ​ 10,199,370 ​ 191,465,083 Lishomwa C. Ndhlovu, M.D., Ph.D. ​ 249,288,063 ​ 9,981,620 ​ 191,465,083 Karen J. Brunke, Ph.D. ​ 251,975,382 ​ 7,294,301 ​ 191,465,083 Ryan Dunlap ​ 252,056,789 ​ 7,212,894 ​ 191,465,083 Stephen M. Simes ​ 252,211,525 ​ 7,058,158 ​ 191,465,083 ​ The stockholders voted to elect each of the Company’s director nominees to serve until the Company’s 2023 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal.

3. Advisory Vote on Compensation of Named Executive Officers ​ For ​ Against ​ Abstentions ​ Broker Non-Votes 215,052,452 34,041,247 10,175,984 ​ 191,465,083 ​ ​ The stockholders voted to approve, on an advisory basis, the compensation paid to the Company’s named executive officers.

2. Ratification of Appointment of Independent Registered Public Accounting Firm ​ ​ ​ For ​ Against ​ Abstentions 434,093,397 5,374,268 11,267,101 ​ The stockholders voted to ratify the selection of Macias Gini & O’Connell LLP as the Company’s independent registered public accounting firm for the fiscal year ending May 31, 2023.